A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Public ClinicalTrials.gov record NCT04035486. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).
Study identification
- NCT ID
- NCT04035486
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 587 participants
Conditions and interventions
Conditions
Interventions
- Osimertinib Drug
- Pemetrexed/Carboplatin Drug
- Pemetrexed/Cisplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 110 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2019
- Primary completion
- Apr 2, 2023
- Completion
- Dec 21, 2026
- Last update posted
- Oct 9, 2025
2019 – 2026
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Bellflower | California | 90706 | — |
| Research Site | Fullerton | California | 92835 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | West Hollywood | California | 90048 | — |
| Research Site | Whittier | California | 90602 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Henderson | Nevada | 89074 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | Canton | Ohio | 44710 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Pittsburgh | Pennsylvania | 15232 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | San Antonio | Texas | 78240 | — |
| Research Site | Blacksburg | Virginia | 24060 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 130 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04035486, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2025 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04035486 live on ClinicalTrials.gov.